Daniel M. Junius - 28 Jan 2022 Form 4 Insider Report for IDEXX LABORATORIES INC /DE (IDXX)

SEC evidence 5 source fields
Form type
4
Accepted by SEC
01 Feb 2022, 16:03:06 UTC
Previous filing
02 Nov 2021
Next filing
03 May 2022
SEC filing
View on sec.gov
Reporting owner 1 detail
Reporting owner signature
/s/ Lily J. Lu, Attorney-in-Fact for Daniel M. Junius

Key filing fact

Daniel M. Junius filed Form 4 for IDEXX LABORATORIES INC /DE (IDXX) on 01 Feb 2022.

Key facts

  • This page summarizes Daniel M. Junius's Form 4 filing for IDEXX LABORATORIES INC /DE (IDXX).
  • 1 reported transaction and 0 derivative rows are listed below.
  • Accepted by SEC: 01 Feb 2022, 16:03.

Change

  • Previous filing in this sequence was filed on 02 Nov 2021.
  • Current net transaction value: +$6,358.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

See Original Filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IDXX transaction

Common Stock

Award

Transaction value
$6,358
Shares
+13
Change %
+0.45%
Price
$489.05
Shares after
2,919
Date
28 Jan 2022
Ownership
Direct
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents deferred stock units acquired pursuant to the IDEXX Laboratories, Inc. Director Deferred Compensation Plan (the "Plan") in accordance with Rule 16b-3. The number of deferred stock units, rounded up or down to the nearest whole unit, is determined by dividing the amount of cash compensation deferred pursuant to the Plan ($6,562.50) by the closing price of IDEXX Laboratories, Inc. common stock on the date of the deferral, or if no such price is reported for that date, the closing price for the next preceding date for which such price was reported. Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The deferred stock units vest immediately upon grant and are payable only as common stock one year following the Director's resignation from the Board of Directors or on such other nondiscretionary and objectively determinable date(s) selected in accordance with the terms of the Plan.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .